The results suggested that antibody tests could be an important product to RNA detection during the illness course, but some special patients with decreased lymphocytes could remain unfavorable of antibody detection results
The results suggested that antibody tests could be an important product to RNA detection during the illness course, but some special patients with decreased lymphocytes could remain unfavorable of antibody detection results. In this study, we analysed the consecutive throat swabs specimens from 187 COVID-19 patients. (39.39%)0.0596b75 (59.06%)13 (36.11%)0.0148bFemale, (%)55 (42.31%)20 (60.61%)?52 (40.94%)23 (63.89%)?Comorbidities??????Diabetes, (%)22 (16.92%)5 (15.15%)0.8069b22 (17.32%)5 (13.89%)0.6247bHypertension, (%)33 delta-Valerobetaine (25.38%)15 (45.45%)0.0239b33 (25.98%)14 (38.89%)0.1314bCardia-cerebrovascular disease, (%)20 (15.38%)11 (33.33%)0.0190b21 (16.54%)10 (27.78%)0.1292bRespiratory diseases, (%)5 (3.85%)3 (9.09%)0.2130b4 (3.15%)4 (11.11%)0.0724bTumor, (%)3 (2.31%)2 (6.06%)0.2665b3 (2.36%)2 (5.56%)0.3051bClinical classification??????Mild, (%)2 (1.54%)0 (0)N/A2 (1.57%)0 (0)N/AGeneral, (%)86 (66.15%)18 (54.55%)0.2153b82 (64.57%)22 (61.11%)0.7033bSevere, (%)23 (17.69%)2 (6.06%)0.1121b23 (18.11%)2 (5.56%)0.0650bCrucial, (%)19 (14.62%)13 (39.39%)0.0014b20 (15.75%)12 (33.33%)0.0190bPositive conversion time for SARS-CoV-2 RNA7.50 (4.00C13.00)5.00 (3.00C7.50)0.0228c8.00 (4.00C13.00)5.00 (3.00C7.00)0.0022cClinical laboratory test??????WBC, 10^9/L5.59 (4.46C7.35)4.86 (3.44C8.58)0.4902c5.63 (4.53C7.42)4.82 (3.40C8.32)0.3250 cNeutrophil, 10^9/L3.47 (2.40C5.17)3.47 (1.85C7.41)0.8751c3.56 (2.44C5.24)3.17 (1.93C7.08)0.5982cLymphocyte, 10^9/L1.30??0.610.90??0.430.0005a1.29??0.610.97??0.490.0046aMonocyte, 10^9/L0.45 (0.33C0.64)0.42 (0.31C0.56)0.3646c0.44 (0.34C0.64)0.42 (0.31C0.56)0.4724cRDW, (%)13.20 (12.68C13.70)13.10 (12.55C13.95)0.9975c13.20 (12.70C13.70)13.05 (12.43C13.90)0.7160cGlucose, mmol/L5.48 (4.86C6.85)5.98 (5.12C6.99)0.2702c5.49 (4.86C7.02)5.82 (5.09C6.77)0.3930cALT, U/L27.00 (18.75C50.25)24.00 (14.50C41.50)0.2106c28.00 (20.00C50.25)20.50 (14.00C39.50)0.0274cAST, U/L25.50 (19.00C30.00)26.00 (19.50C51.00)0.5849c26.00 (19.00C40.00)25.50 (16.50C47.75)0.5491cBUN, mmol/L4.56 (3.71C5.66)5.21 (3.49C8.36)0.1119c4.55 (3.72C5.65)5.15 (3.53C7.91)0.1291cCRP, mg/L8.45 (2.08C46.15)15.23 (3.03C43.90)0.5316c8.90 (2.00C48.70)10.90 (2.95C44.15)0.6416c Open in a separate window Data was displayed as mean??SD, median (IQR, interquartile range), or (%). atwo-tailed Students test btest) Positive conversion time for SARS-CoV-2 RNA defined as the first positive time point of RNA assessments. p?p?=?0.001 for IgM, p?=?0.006 for IgG) and SARS-CoV-2 RNA positive conversion time (p?=?0.014 for IgM, p?=?0.003 for IgG) were positively associated with antibody delta-Valerobetaine positive results, while, the critical patients had a higher negative rate of IgM (p?=?0.002) and IgG (p?=?0.022). Additionally, cardiovascular and cerebrovascular diseases negatively associated with IgM positive results (p?=?0.022), and the male (p?=?0.017) and serum ALT level (p?=?0.029) positively associated with IgG positive results. Multivariate logistic regression models indicated that this lymphocyte counts (p?=?0.017 for IgM, p?=?0.043 for IgG) and SARS-CoV-2 RNA positive conversion time (p?=?0.014 for IgM, p?=?0.003 for IgG) were the indie influence factors for antibody positive results after the adjustment for demographic and clinical characteristics. In addition, gender was also an independent factor that affecting IgG detection (p?=?0.032). Table 3. Univariate and multivariate binary logistic analysis of influencing factors of IgM / IgG result view.
Age0.98 (0.96C1.01)0.2151.00 (0.97C1.04)0.9870.99 (0.96C1.01)0.3511.00 (0.96C1.03)0.804Gender2.10 (0.96C4.58)0.0632.61 (0.92C7.42)0.0722.55 (1.19C5.49)0.0173.05 (1.10C8.48)0.032Comorbidities????????Diabetes1.14 (0.40C3.28)0.8071.53 (0.37C6.30)0.5541.30 (0.45C3.71)0.6251.67 (0.40C6.96)0.481Hypertension0.46 (0.21C1.02)0.0570.45 (0.14C1.42)0.1740.55 (0.25C1.20)0.1340.46 (0.14C1.46)0.186Cardia-cerebrovascular disease0.36 (0.15C0.87)0.0220.65 (0.18C2.42)0.5230.52 (0.22C1.23)0.1341.04 (0.26C4.11)0.952Respiratory delta-Valerobetaine diseases0.40 (0.91C1.77)0.2270.32 (0.05C1.91)0.2090.26 (0.06C1.10)0.0670.15 (0.03C0.90)0.038Tumor0.37 (0.60C2.29)0.2820.19 (0.02C2.04)0.1720.41 (0.07C2.56)0.3410.20 (0.02C2.23)0.192Clinical classification????????MildN/A?N/A?N/A?N/A?General0.61 (0.28C1.33)0.2181.0 (Ref.)?0.86 (0.40C1.85)0.7031.0 (Ref.)?Severe0.30 (0.07C1.34)0.1162.90 (0.49C17.09)0.2390.27 (0.60C1.19)0.0833.34 (0.55C20.37)0.191Critical0.26 (0.11C0.62)0.0020.35 (0.07C1.71)0.1970.37 (0.16C0.87)0.0220.35 (0.07C1.78)0.206Positive conversion time for SARS-CoV-2 RNA1.11 (1.02C1.21)0.0141.16 (1.03C1.31)0.0141.14 (1.05C1.25)0.0031.21 (1.07C1.38)0.003Clinical laboratory test????????WBC, 10^9/L1.01 (0.91C1.11)0.900??1.01 (0.92C1.12)0.793??Neutrophil, 10^9/L0.98 (0.89C1.07)0.644??0.99 (0.90C1.09)0.822??Lymphocyte, 10^9/L3.91 (1.73C8.821)0.0013.48(1.25C9.71)0.0172.77 (1.34C5.74)0.0062.68 (1.03C6.99)0.043Monocyte, 10^9/L1.68 (0.30C9.47)0.559??1.30 (0.25C6.69)0.755??RDW, (%)0.82 (0.66C1.03)0.088??0.85 (0.68C1.06)0.157??Glucose, mmol/L0.96 delta-Valerobetaine (0.84C1.10)0.568??0.99 (0.86C1.13)0.843??ALT, U/L1.02 (1.00C1.03)0.0871.02( 0.99C1.04)0.2201.02 (1.00C1.04)0.0291.02 (0.99C1.04)0.151AST, U/L1.00 (0.99C1.01)0.929??1.01 (0.99C1.02)0.501??BUN, mmol/L0.95 (0.90C1.01)0.122??0.98 (0.92C1.04)0.406??CRP, mg/L1.00 (1.00C1.01)0.485??1.00 (1.00C1.01)0.375?? Open in a separate windows Abbreviation: WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; RDW, red blood cell distribution width; IL-6, interleukin-6; N/A, not applicable; Ref, reference. p? 45, Figure 1, Supplementary Table S1). Notably, there were 27 patients (14.44%, 27/187) underwent multiple negative nucleic acid tests before confirmed diagnosis were made. This indicated that in addition to multiple assessments for RNA with the same patient,.